OVID
Ovid Therapeutics Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.38
P/S
45.82
EV/EBITDA
-7.95
DCF Value
$-0.92
FCF Yield
-11.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.2%
Operating Margin
-585.2%
Net Margin
-240.1%
ROE
-24.0%
ROA
-11.5%
ROIC
-29.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $718.0K | $9.7M | $0.12 |
| FY 2025 | $7.3M | $-17.4M | $-0.24 |
| Q3 2025 | $132.0K | $-12.2M | $-0.17 |
| Q2 2025 | $6.3M | $-4.7M | $-0.07 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-0.03
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.